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Nonsteroidal Anti-Inflammatory Drugs Induce
Apoptosis in Cutaneous T-Cell Lymphoma Cells
and Enhance Their Sensitivity for TNF-Related
Apoptosis-Inducing Ligand
Frank K. Braun1, Nadya Al-Yacoub1, Michael Plo¨tz1, Markus Mo¨bs1, Wolfram Sterry1 and Ju¨rgen Eberle1
Cutaneous T-cell lymphomas (CTCL) form a heterogeneous group of non-Hodgkin’s lymphomas of the skin. In
previous studies, we had characterized CTCL cells as resistant to the death ligand tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL), which correlated to pronounced expression of the caspase-8/-10 inhibitor
c-FLIP. For identification of proapoptotic strategies in CTCL cells and for overcoming their death ligand
resistance, we investigated the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic
acid, sodium salicylate, and diclofenac (DF). These drugs strongly enhanced apoptosis, as well as decreased
CTCL cell proliferation and vitality, and DF furthermore sensitized for TRAIL-induced apoptosis. Full activation
of the caspase cascade (caspase-3, -8, -9) and decreased mitochondrial membrane potential were characteristic
for NSAID treatment, whereas cytochrome c release was seen only for DF. Downregulation of Mcl-1 and
enhanced surface expression of TRAIL were seen in response to NSAIDs. Most characteristic for apoptosis
induction was the downregulation of c-FLIP. In agreement with the critical role of c-FLIP for apoptosis deficiency
of CTCL cells, its overexpression decreased NSAID-mediated apoptosis and its downregulation by small hairpin
RNA-enhanced apoptosis. The study provides a rationale for the use of NSAIDs as a new therapeutic option for
CTCL patients. Supporting this concept, ex vivo lymphoma cells of CTCL patients also revealed significant
sensitivity for NSAID treatment.
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INTRODUCTION
Non-Hodgkin’s lymphomas have shown increasing inci-
dence in past decades, with a prevalence of 10–20 cases
per 100,000 in Western countries at present (Muller et al.,
2005). Roughly 5% of non-Hodgkin’s lymphomas are
characterized by clonal proliferation of skin-homing memory
T lymphocytes and primary cutaneous manifestation. The
heterogeneous group of cutaneous T-cell lymphomas (CTCL)
encloses as its most frequent entities mycosis fungoides,
Se´zary syndrome (SzS), and CD30(þ ) lymphoproliferative
disorders. CTCL frequently reveals a rather indolent clinical
course in the beginning, but may transform in its late phases
to a phenotype with rapidly growing and ulcerating tumors
(Willemze et al., 2005).
The principal goal of cancer therapy is the elimination of
tumor cells through induction of apoptosis. Thus, therapy
resistance is frequently explained in terms of defects in
apoptosis signaling (Reed and Pellecchia, 2005; Eberle et al.,
2007). Extrinsic proapoptotic pathways are initiated by death
ligands as tumor necrosis factor-a, CD95L/FasL, and TRAIL
(tumor necrosis factor-related apoptosis-inducing ligand),
which exert particular functions in an antitumor immune
response, as well as in lymphocyte autoregulation. Their
binding to death receptors results in the formation of a death-
inducing signaling complex, where proapoptotic initiator
caspases 8 and 10 are activated (Krammer et al., 2007). These
caspases are negatively regulated by c-FLIP (cellular FLICE-
inhibitory protein), a catalytically inactive caspase-8 homo-
log that binds to the death-inducing signaling complex in a
competitive manner (Irmler et al., 1997).
Death receptor-mediated apoptosis may be further en-
hanced in an amplification loop by the mitochondrial
proapoptotic pathway, which is critically regulated by the
Bcl-2 protein family (Reed, 2008). This is mediated by
cleavage and activation of the proapoptotic Bcl-2 protein
Bid through caspase-8 (Li et al., 1998). Activation of the
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mitochondrial apoptosis pathway results in the release of
proapoptotic factors such as cytochrome c and subsequent
activation of initiator caspase-9. Initiator caspases 8, 9, and
10 may cleave and activate the main effector caspase-3,
which cleaves a large number of death substrates for
complete reprogramming of the cell with the final result of
DNA fragmentation (Fischer et al., 2003).
Resistance to apoptosis appears as a critical feature of
cancer cells, as also seen in CTCL. Thus, loss of the death
receptor CD95/Fas (Contassot et al., 2007, 2008), impaired
activation-induced cell death due to disrupted T-cell receptor
signaling (Klemke et al., 2009), and constitutive activation of
pro-survival transcription factors such as NF-kB (Sors et al.,
2006) have been reported. Particularly, c-FLIP appears as a
promising target. Its dysregulated expression has been
recognized in different cancer entities, including Hodgkin’s
lymphoma (Mathas et al., 2004), and it has been described by
us recently as constitutively expressed in CTCL cells (Braun
et al., 2007, 2010).
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely
used in the clinic for treatment of pain and inflammation, and
have also been established in anti-cancer therapies recently
(Cha and Dubois, 2007). Cyclooxygenases (COX-1, COX-2),
which catalyze prostaglandin synthesis, are important targets
of NSAIDs (Castellone et al., 2005; Samuelsson et al., 2007).
Aberrant COX-2 expression was related to tumor growth as in
colorectal carcinoma (Clevers, 2006), cutaneous squamous
cell carcinoma (Fecker et al., 2010), and hematological
malignancies (Kopp et al., 2010). Selective COX-2 inhibitors
such as celcoxib, valdecoxib, and rofecoxib are distinguished
from nonselective inhibitors targeting both COX-1 and
COX-2, such as sulindac, acetylsalicylic acid (ASA), sodium
salicylate (NaS), and diclofenac (DF).
Here, we describe significant anti-neoplastic effects of
NSAIDs (ASA, NaS, DF) in CTCL cell lines, as well as in
ex vivo tumor T cells of CTCL patients, which may provide
a basis for the use of NSAIDs in CTCL therapy.
RESULTS
NSAIDs decrease cell proliferation and induce apoptosis in
CTCL cells
For overlooking the effects of NSAIDs in CTCL cells, HH,
MyLa, HuT-78, and SeAx cell lines were treated for 40 hours
with increasing concentrations of ASA and NaS (1–5mM).
Because of different sensitivities seen for DF in pilot experi-
ments, 5–60 mgml1 was used for HH and 30–120 mgml1
was used for MyLa, HuT-78, and SeAx (Figure 1b). For time
kinetic analyses, cells were treated for 16, 40, and 72 hours,
respectively. Here, concentrations of 5mM were used for
ASA and NaS (5mM), whereas DF was used at concentrations
of 60 mgml1 (HH) or 120mgml1 (MyLa, HuT-78, SeAx;
Figure 1h).
According to WST-1 proliferation assays, significant dose-
and time-dependent decrease of cell proliferation (between
40 and 70%, at 72 hours) was seen in all cell lines and for all
treatments (Figure 1a and g). The decrease of mitochondrial
enzyme activity (WST-1) was in parallel with the direct cell
counts, but appeared stronger, indicating an additional effect
on cell vitality (Figure 1f). Cytotoxicity appeared to have
no major role, and was seen only in MyLa and HuT-78
after treatment with higher concentrations of DF and NaS
(Figure 1c).
In parallel with decreased cell numbers, significant dose-
and time-dependent increase of apoptosis was observed by
the NSAIDs in all cell lines. Values of 80% apoptotic cells in
HuT-78 and 40% in HH at 72 hours suggested a decisive role
of apoptosis induction in these cells. Apoptosis was signifi-
cantly less in MyLa and SeAx when treated with ASA and DF
(10–20%), and did not occur after NaS treatment. Thus, in
these cells, inhibited cell proliferation appeared to play the
major role, also seen by strongly decreased WST-1 values at
16 hours, when apoptosis was still weak (Figure 1g and h). In
agreement, a G2 cell cycle arrest was frequently seen in
DF-treated MyLa and SeAx (Figure 1d and e). Thus, NSAIDs
exerted substantial anti-neoplastic effects on CTCL cells
related to apoptosis induction and decreased cell viability
and cell proliferation.
Caspase activation by NSAIDs
For unraveling the signaling pathways, the initiator caspases-
8 and -9, the main effector caspase-3, and Bid were
investigated by western blot analysis. Strong and dose-
dependent processing of caspase-8 and -3 was seen at
24 hours after NSAID treatment. Reduced levels of the Bid
proform indicative of its activation were also seen in MyLa
after DF treatment (60 mgml1), and weak caspase-9 proces-
sing was evident in HH (Figure 2a).
Caspase involvement was further proven by the caspase
inhibitor Q-VD-Oph, which significantly decreased NSAID-
induced apoptosis (Figure 2b). For control, cells were also
treated with an agonistic anti-CD95 antibody (CH-11,
50 ngml1, 40 hours). This caspase-dependent induction of
apoptosis was completely abrogated by Q-VD-Oph. Thus,
the partially remaining proapoptotic activity in HH after
Figure 1. Nonsteroidal anti-inflammatory drugs (NSAIDs) decrease cell proliferation and induce apoptosis in cutaneous T-cell lymphoma cells. (a–c) For
determination of dose response, HH, MyLa, HuT-78, and SeAx were incubated for 40hours with increasing concentrations of acetylsalicylic acid (ASA) and
sodium salicylate (NaS; 1–5mM), as well as diclofenac (DF; 5–120mgml1). (g, h) For time kinetic analysis, cells were harvested at 16, 40, and 72hours of
treatment. Here, ASA and NaS were used at concentrations of 5mM, and DF was used at 60mgml1 for HH and 120mgml1 for MyLa, HuT-78, and SeAx. (a, g)
Cell proliferation was determined by WST-1 assay, and values are expressed as percentage of nontreated controls (C¼ 100%). (b, h) Apoptosis was quantified
according to propidium iodide staining. Mean values±SDs of at least six values are shown. (c) Cytotoxicity was determined by lactate dehydrogenase release
assay, and relative values were calculated with respect to untreated controls (C¼ 1). (d) Representative histograms of DF-treated cells as determined by flow
cytometry are shown. Apoptotic sub-G1 (sG1) cells, G1 and G2 populations are indicated. (e) Quantification of G2 population is shown for NSAID-treated
(16hours) MyLa cells. The result was highly similar for the three other cell lines (data not shown). (f) Cell numbers were determined using a CASY Cell Counter
and presented for HH as percentage of nontreated controls (C¼ 100%). The result was highly similar for MyLa (data not shown). *Indicates statistical significance.
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NSAID treatment was indicative of additional, proapoptotic
but caspase-independent pathways.
Mitochondrial activation and NF-jB signaling
Decreased mitochondrial membrane potential (Dcm), a
hallmark in mitochondrial activation, was seen in HH by
all three NSAIDs and in MyLa by ASA and DF (Figure 3a). A
lack of Dcm decrease, seen in MyLa by NaS, correlated with a
limited proapoptotic activity.
For further analysis of intrinsic apoptosis pathways,
mitochondrial and cytosolic fractions of HH and MyLa were
investigated for cytochrome c release and Bax translocation.
Cells were treated for 24 hours or for 40 hours, and
concentrations were at 5mM for ASA and NaS or at
60 mgml1 for DF. In contrast to the general loss of Dcm,
release of cytochrome c and Bax translocation was seen only
in DF-treated MyLa at 40 and 24 hours (Figure 3c and data
not shown). In parallel, increased reactive oxygen species
(ROS) levels were evident in DF-treated MyLa (Figure 3d).
Thus, full activation of the mitochondrial apoptosis pathway
appeared as characteristic for DF-treated MyLa, whereas
decrease of Dcm in other conditions was indicative of
mitochondrial dysfunction.
NF-kB signaling pathways were investigated by monitor-
ing nuclear localization of the NF-kB subunits p65, p50, and
p52 by western blot analysis in HH and MyLa cells at
16 hours of treatment. In addition, the DNA-binding capacity
was monitored in nuclear extracts by an ELISA for NF-kB
family members. Both assays revealed largely comparable
data, namely clear downregulation of nuclear p65 in
response to NSAID treatment in HH. Similarly, MyLa showed
a clear tendency to downregulation of p65 and p52 nuclear
levels in response to DF, as well as downregulation of p52 in
response to ASA (Figure 3e and f). Thus, NF-kB pathways
appeared as downregulated by NSAIDs in CTCL cells. Largely
excluding any proapoptotic function of NF-kB in this setting,
the I-kB kinase inhibitor BMS-345541 did not reduce
apoptosis induction by DF in HH and MyLa cells (Figure 3g).
Critical role of c-FLIP in NSAID-induced apoptosis
For understanding the roles of pro- and antiapoptotic
mediators in NSAID-mediated apoptosis, the expression of
key regulators was investigated by western blot analysis.
Whereas no significant changes were evident for Bax, Bcl-2,
and XIAP, the antiapoptotic Bcl-2 protein Mcl-1 was down-
regulated with higher concentrations of ASA (5mM) and DF
(60 mgml1). In addition, the antiapoptotic and pro-prolif-
erative factor survivin was downregulated in HH and MyLa
by NaS, which may contribute to its effects in these cells. On
the other hand, survivin appeared as upregulated by DF in
HH, which may be seen as a counter-regulatory response.
The caspase-8/-10 inhibitor c-FLIP appeared to be of
particular importance. Both isoforms (FLIPL/S) were down-
regulated in HH and MyLa by ASA and DF. In addition, NaS
resulted in a downregulation of FLIPS in HH (Figure 3h). An
even stronger downregulation of c-FLIP isoforms was
detected at 40 hours of DF treatment (Figure 5c).
To prove the role of c-FLIP in NSAID-induced apoptosis,
viral vectors were used for its overexpression and small
hairpin RNA (shRNA) for its downregulation. Apoptosis
induction by ASA, NaS, or DF was significantly diminished
in MyLa cells when transduced with a retroviral vector for
FLIPL overexpression, whereas mock-transduced cells
showed a similar response as parental cells (Figure 4a).
Proving the function of c-FLIP, apoptosis by stimulation of
CD95 (CH-11 agonistic antibody) was similarly reduced in
FLIP-transduced cells (Figure 4a). A high transduction
efficiency was monitored by green fluorescent protein
(GFP) expression (70–90% GFPþ cells, Figure 4b), and
FLIPL overexpression was shown by western blot analysis
(Figure 4c).
Targeting c-FLIP expression by a lentiviral cFLIPRNAi vector
demonstrated the important role of c-FLIP for CTCL cell
survival. Strongly enhanced spontaneous apoptosis was
characteristic for cFLIPRNAi-transduced HH and MyLa cells,
as compared with controls. Transduction of a ScrambleRNAi
construct proved that the transduction itself had only little
effect on apoptosis (Figure 4d). Additional effects of NSAIDs
could not be examined in these cells, owing to the high
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Figure 2. Activation of the caspase (Csp) signaling cascade by nonsteroidal
anti-inflammatory drugs. (a) Processing of caspases and Bid (western blotting)
is shown for HH and MyLa treated for 24 hours with acetylsalicylic acid (ASA;
3, 5mM), sodium salicylate (NaS; 3, 5mM), or diclofenac (DF; 30, 60mgml1).
Nontreated cells served as controls (C). Equal loading was confirmed by
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. (b) HH
and MyLa were pretreated for 1 hour with Q-VD-Oph, followed by treatment
with ASA (5mM), NaS (5mM), or DF (60 mgml1) for additional 24 hours.
As a control, cells were treated for 40 hours with an agonistic anti-CD95
antibody (CH-11, 50 ngml1). Apoptosis was quantified by propidium
iodide staining. Means±SDs of a representative experiment with
triplicate values are shown. Another experiment revealed similar results.
*Indicates statistical significance.
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Figure 3. Loss of Dwm and downregulation of c-FLIP. (a) Loss of Dcm in HH and MyLa treated with acetylsalicylic acid (ASA; 5mM), sodium salicylate (NaS;
5mM), or diclofenac (DF; 60mgml1) was determined by tetramethylrhodamine methyl ester perchlorate (TMRMþ ) staining (means±SDs of at least six individual
values). (b) Representative histograms of nonsteroidal anti-inflammatory drug (NSAID)-treated cells (gray) in overlays with nontreated controls (C; white).
The bar indicates the populations with low Dcm. (c) Mitochondrial (Mito) and cytosolic (Cyto) fractions of MyLa treated with NSAIDs for 40hours (concentrations
as in a) were investigated for cytochrome c (Cyto c) release and Bax translocation. Lane 1: cytosolic and mitochondrial controls. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) proved equal loading of cytosolic extracts and voltage-dependent anion channel (VDAC) excluded contamination of cytosolic extracts
with mitochondria. (d) Reactive oxygen species (ROS) levels, according to dichlorodihydrofluorescein diacetate staining, are shown in response to DF (60mgml1;
repeated twice). (e) Nuclear localization of NF-kB subunits (p65, p50, and p52) is shown by western blot analysis in HH and MyLa cells treated for
16hours with NSAIDs (ASA and NaS 5mM, DF 60mgml1 for HH and 120mgml1 for MyLa). Lamin expression and ponceau staining proved equal loading.
(f) Relative DNA-binding capacity of p65 in nuclear extracts of HH cells treated for 16 hours with NSAIDs is shown as fold change. (g) Apoptosis induction in HH
and MyLa cells pretreated with BMS-345541 (3mM) for 3 hours, followed by NSAID treatment for additional 40hours is shown. Apoptosis was quantified
according to propidium iodide staining. Mean values±SDs of a representative experiment are given. (h) Expression of c-FLIP, Bax, Bcl-2, Mcl-1, XIAP, and
survivin is shown by western blotting in cutaneous T-cell lymphoma cells treated for 24 hours with ASA (3, 5mM), NaS (3, 5mM), and DF (30, 60mgml1).
Equal loading was confirmed by GAPDH and c-FLIP expression was quantified by densitometriy (fold change). The whole experiment was performed twice.
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background of dying cells. After a few days, no GFP-positive
cells remained. These complementary approaches were
clearly indicative of the dependency of CTCL cell survival
on c-FLIP expression.
Enhancement of TRAIL-induced apoptosis by DF
Death ligands are critical for autoregulation of T lympho-
cytes. Thus, the expression of TRAIL and TRAIL-R2/DR5 was
determined after NSAID treatment. Indeed, TRAIL surface
expression was increased in HH cells by all NSAIDs
(Figure 5a, upper panel), whereas MyLa cells did not reveal
significant TRAIL expression (data not shown). Both cell lines
were characterized by strong surface expression of DR5,
which, however, did not change significantly upon treatment
(Figure 5a, lower panel).
With regard to the resistance of CTCL cells to TRAIL, we
investigated whether NSAID treatment might sensitize for
TRAIL-induced apoptosis. Indeed, enhanced TRAIL sensitivity
was seen in both cell lines after treatment with DF, whereas
ASA or NaS were without effect here. Pre-incubation with DF
(60 mgml1, 24 hours) followed by addition of TRAIL and
combined incubation for another 16 hours resulted in 25%
and 45% apoptotic cells in MyLa and HH, respectively
(Figure 5b).
Enhanced apoptosis was accompanied by enhanced
caspase activation, evident by strong processing of caspase-
3, -8, and -9. The strongly reduced expression of c-FLIP by DF
at 40 hours (Figure 5c) appeared to be of particular
importance for the enhanced TRAIL sensitivity.
Correlation of in vitro and ex vivo data
For proving the impact of the in vitro findings for the clinical
setting, the responsiveness of tumor T cells isolated from four
SzS patients was investigated and compared with CD4(þ )
control T cells of four healthy donors (both enriched up to
90%). Clinical information of SzS patients is summarized in
Table 1. Significantly enhanced apoptosis was seen in tumor
T cells treated for 40 hours with ASA (5mM), NaS (5mM), and
DF (60 mgml1), whereas cytotoxicity remained at a low level
(Figure 6). A proapoptotic response was also seen in CD4(þ )
normal T cells, possibly indicative of COX-2-independent
effects (Figure 6). A second set of tumor T-cell preparations
isolated from the same patients at 2–4 weeks later revealed
largely comparable sensitivity (data not shown), thus demon-
strating the principle responsiveness of patient’s tumor T cells
to NSAIDs.
DISCUSSION
Defective apoptosis signaling is critical for therapy resistance
and poor prognosis in neoplastic disease, and thus activation
of proapoptotic pathways is a primary goal in cancer therapy
(Reed and Pellecchia, 2005; Eberle et al., 2007). The death
ligand TRAIL is a promising antitumor agent with a
preference for apoptosis induction in tumor cells (Newsom-
Davis et al., 2009), but induced resistance may limit its
clinical applicability. Furthermore, death ligands are of
particular significance for lymphomas, because of their
important role in controlling lymphocyte self-regulation (Li-
Weber and Krammer, 2003; Janssen et al., 2005). Resistance
to the CD95/CD95L-mediated control has been reported in
CTCL cells and related to impaired TCR signaling and loss of
the receptor CD95 (Contassot et al., 2008; Klemke et al.,
2009). In previous studies, we have identified the pro-
nounced resistance of CTCL cell lines to TRAIL-induced
apoptosis, which was related to enhanced expression of
c-FLIP (Braun et al., 2007, 2010).
TRAIL resistance and c-FLIP expression may depend on
NF-kB-mediated transcriptional regulation (Micheau et al.,
2001), and constitutive activation of NF-kB has been reported
in CTCL cells, suggesting c-FLIP and possibly other NF-kB
targets as important therapeutic targets (Sors et al., 2006,
2008). As a further example, inhibition of NF-kB was
reported to lead to reduced levels of ferritin heavy chain in
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western blot analysis as compared with mock- and non-transduced cells. (d)
Spontaneous apoptosis (PI staining) of untreated cells in response to
transduction with cFLIPRNAi lentivirus (FL) as compared with ScrambleRNAi
lentivirus (Sc) and non-transduced controls (C). Means±SDs of two
independent experiments, each performed in triplicates, are shown.
*Indicates statistical significance. GAPDH, glyceraldehyde-3-phosphate
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CTCL cells, thus increasing ROS levels to induce apoptosis
(Kiessling et al., 2009). As c-FLIP appeared to be of particular
significance for TRAIL resistance, we looked for strategies to
downregulate c-FLIP, thus restoring TRAIL sensitivity and
decreasing lymphoma growth due to a reactivation of self-
regulatory programs.
NSAIDs are in clinical use for years, and COX-dependent
and independent effects have been attributed to their mode of
action (Jana, 2008). Particularly, COX-2 appears as frequently
upregulated in tumor cells (Greenhough et al., 2009; Kopp
et al., 2010). The antitumor activities of NSAIDs had been
recognized for colorectal cancer, and NSAIDs are used to
treat patients with familial adenomatous polyposis (Cole
et al., 2009).
With regard to T-cell lymphomas, however, solid data on
the impact of NSAIDs are still scarce. Recently, COX-2
expression has been proven in CTCL cells, and treatment with
the selective COX-2 inhibitor celecoxib resulted in decreased
cell growth and viability (Kopp et al., 2010). However, severe
side effects such as heart failure have also been reported for
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Figure 5. Enhancement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by combination with diclofenac. (a) Cutaneous
T-cell lymphoma (CTCL) cells were treated for 24 hours with acetylsalicylic acid (ASA; 5mM), sodium salicylate (NaS; 5mM), and diclofenac (DF; 60mgml1).
Surface expression of TRAIL (filled graphs, upper panel) and TRAIL-R2/DR5 (filled graphs, lower panel) in HH are shown in overlay histograms as compared with
isotype controls (open graphs). Two experiments yielded similar results. (b) CTCL cells were treated for 40 hours with ASA (5mM), NaS (5mM), or DF
(60mgml1). TRAIL was added for the last 16 hours, when indicated. Apoptosis was quantified by propidium iodide staining. Mean values±SDs of a
representative experiment are shown (two independent in triplicates). (c) Diclofenac and TRAIL-treated HH and MyLa cells were investigated by western blot
analysis for caspase activation and c-FLIP expression. Caspase (Csp) cleavage products are indicated as ( ). Equal loading was confirmed by glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression. The experiment was repeated once, yielding highly comparable results.
*Indicates statistical significance. NSAID, nonsteroidal anti-inflammatory drugs.
Table 1. SzS patient clinical data
Patient Age (y) Sex Diagnosis WBC1 Tumor cell2 Therapy
1 64 F SzS 30 90 INF, ECP, Ch+Pr, PUVA, MTX, Cyc, Bex+SAHA
2 73 M SzS 30 99 UV, ECP
3 62 F SzS 18 90 ECP
4 55 F SzS 3.1 NA ECP + INF
Abbreviations: Bex, bexarotene; Ch, chlorambucil; Cyc, cyclophosphamide; ECP, extracorporeal photopheresis; F, female; M, male; MTX, methotrexate;
NA, not available; Pr, prednisone; PUVA, psolaren+UV; SAHA, suberoylanilide hydroxamic acid; SzS, Se´zary syndrome; WBC, white blood cell; y, years.
1WBC count per nanoliter.
2Tumor cell load at the time of analysis was determined according to Vbeta staining (patient 1) or according to atypical lymphocytes (Se´zary cells;
patients 2, 3).
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the selective COX-2 inhibitors, and valdecoxib and rofecoxib
had to be recalled from the market (Bresalier et al., 2005;
Nussmeier et al., 2005). Thus, nonselective COX inhibitors,
namely ASA, NaS, and DF, were applied here in doses
comparable to their clinical use. Thus, daily doses of up to 5 g
salicylates used in high-dose treatment of type 2 diabetes
(Rumore and Kim, 2010) account for a theoretical blood
concentration of 1mgml1. On the other hand, 5mM ASA
used in our experiments correspond to almost the same
concentration of 0.9mgml1. Of course, because of phar-
macokinetics the active concentrations in the blood may be
much less, but on the other hand long-term treatment and/or
higher concentrations in topical applications may be applied
for CTCL.
As for CTCL cell lines, NSAID treatment resulted in strong
dose- and time-dependent reduction of cell proliferation,
comparable to the effects of sulindac (Zhang et al., 2003).
Apoptosis induction, inhibition of cell proliferation, and cell
vitality may be related to a common signaling cascade, but
they may be self-consistent and cooperative in enhancing the
anti-neoplastic efficacy. In some types of cells, apoptosis
appeared as the dominant effect, whereas in others inhibition
of cell proliferation appeared to have the decisive role.
With regard to the mechanisms of NSAID-induced
apoptosis in CTCL cells, indications for the activation of
different pathways were seen. Thus, activation of caspase-8
and -3 was evident after treatment with all three NSAIDs,
suggesting an involvement of extrinsic apoptosis pathways.
Besides, caspase-independent pathways may have contribu-
tory roles, as caspase inhibitors did not completely abrogate
NSAID-induced apoptosis. Caspase-independent apoptosis
by NSAIDs has also been discussed previously (Jana, 2008).
However, typically involved mediators such as ROS or the
release of mitochondrial factors have not been observed here.
The downregulation of survivin detected after NaS treatment
may have a contributory role, as related with anti-apoptosis
and cell proliferation (Altieri, 2010).
In Jurkat systemic T-cell lymphoma cells, celecoxib-
mediated apoptosis was related to mitochondrial activation
via Bak, and extrinsic apoptosis pathways had been largely
excluded (Jendrossek et al., 2003). Also in CTCL cells, we
saw mitochondrial activation as decreased mitochondrial
membrane potential. Bax translocation and cytochrome c
release was seen in DF-treated MyLa. Interestingly, HH cells
showed no cytochrome c release and Bax translocation,
which may be related to their lack of Bid expression (Braun
et al., 2007). Thus, high responsiveness of HH may indicate
the dominance of extrinsic apoptosis pathways in CTCL cells.
The mitochondrial pathway is critically controlled by pro-
and antiapoptotic Bcl-2 proteins. Downregulation of Mcl-1
seen here after NSAID treatment may have a role in DF-
treated MyLa; however, this was also seen under conditions
in which NSAIDs did not induce cytochrome c release, and
therefore appears not as sufficient for activating the mito-
chondrial pathway in CTCL cells.
The decreased mitochondrial membrane potential seen
here may result from NSAID-mediated uncoupling of the
electron transport chain, as had been reported for salicylates
in hepatocytes (Chan et al., 2005). As also caspase-9
activation was only weak in CTCL cells in response to
NSAIDs, we may conclude that mitochondrial pathways
were less important here.
Because of the dominant role of c-FLIP in apoptosis
resistance of CTCL cells (Braun et al., 2007), its general
downregulation after NSAID treatment was of particular
interest. In addition, in cutaneous squamous cell carcinoma
(SCC) cell lines, downregulation of c-FLIP in response to DF
had been seen (Fecker et al., 2010). Strongly supporting an
important role of c-FLIP downregulation in NSAID-mediated
apoptosis in CTCL cells, its overexpression diminished
apoptosis induction and in contrast its downregulation by
RNA interference (RNAi) significantly induced spontaneous
apoptosis. CTCL cells were also not able to survive more than
a few days. These complementary approaches strengthened
the particular role of c-FLIP for survival of CTCL cells.
As c-FLIP is a known target of NF-kB (Micheau et al.,
2001), this pathway might also be of importance for NSAID-
induced apoptosis in CTCL cells. NSAIDs may indeed
interfere with NF-kB signaling pathways as shown for
salicylates and DF, which may bind and block I-kB kinase,
thus preventing NF-kB activation (Kopp and Ghosh, 1994;
Fredriksson et al., 2011). NSAIDs may also interfere with
proteasome functions, thus leading to a stabilization of I-kB
(inhibitor of NF-kB; (Dikshit et al., 2006). In agreement with
these reports, our study revealed an inhibition of NF-kB
signaling in CTCL cells by NSAIDs.
In line with the downregulation of c-FLIP, there was a
clear sensitization for TRAIL-induced apoptosis by DF, thus
showing a suitable strategy for overcoming TRAIL resistance
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Figure 6. Nonsteroidal anti-inflammatory drugss induce apoptosis in tumor
T cells of cutaneous T-cell lymphoma patients. Tumor T cells of Se´zary
syndrome (SzS) patients (Pat 1–4) and CD4(þ ) control T cells of healthy
donors (HD, one is shown here) were treated for 40 hours with acetylsalicylic
acid (ASA; 5mM), sodium salicylate (NaS; 5mM), and diclofenac (DF;
60mgml1). Apoptosis was quantified by propidium iodide staining (upper
panel). Relative cytotoxicity was determined according to lactate
dehydrogenase release. Values were normalized with respect to nontreated
controls (C¼ 1, lower panel). Mean values of triplicates±SDs are shown.
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of CTCL. In addition, in other cell types, such as in cutaneous
SCC cells, DF enhanced death ligand sensitivity (Fecker et al.,
2010). The fact that NaS and ASA did not enhance TRAIL
sensitivity indicates principle differences in the mode of
action of these drugs. Expression of TRAIL itself was
upregulated in HH cells by NSAID treatment, which may
further enhance extrinsic induction of apoptosis.
As a further step for proving the clinical applicability
of NSAIDs in CTCL, significant responsiveness of SzS tumor
T cells, treated ex vivo, is demonstrated here. Some sensitivity
also seen in normal CD4(þ ) T cells might be indicative of
possible side effects, which may have to be compared with the
antitumor efficacy in clinical trials. Some NSAIDs are already
approved for treatment of different cancer entities, such as DF
for actinic keratosis (Ulrich et al., 2010), whereas others are
used in clinical trials, such as ASA for breast cancer (Agrawal
and Fentiman, 2008) or celecoxib for colon carcinoma (Half
and Arber, 2009). Overall, we demonstrate that NSAIDs exert
substantial antitumor activities in CTCL cells by activation of
caspases, downregulation of c-FLIP, upregulation of TRAIL, as
well as by affecting cell proliferation. Taking into account the
extensive experience with NSAIDs and a limited side effect
profile, we may suggest the consideration of using NSAIDs
alone or in combinations for therapy of CTCL.
MATERIALS AND METHODS
Cell culture
The CTCL cell lines MyLa (Kaltoft et al., 1992), HH (Starkebaum
et al., 1991; CRL-2105, ATCC, Manassas, VA), HuT-78 (Gootenberg
et al., 1981), and SeAx (Kaltoft et al., 1987) were grown in RPMI with
L-glutamine and 10% fetal calf serum at 37 1C, 5% CO2. For
apoptosis induction, KillerTRAIL (Alexis, Gruenberg, Germany,
20 ngml1), agonistic anti-CD95 antibody (CH-11, Beckman Coul-
ter, Krefeld, Germany; 50 ngml1), ASA (Caelo, Hilden, Germany,
1–5mM, corresponding to 0.18–0.9mgml1), NaS (Sigma-Aldrich,
Taufkirchen, Germany; 1–5mM), and DF (DF, Sigma, 5–120 mgml1)
were used. Treatments were started at 24 hours after seeding. The
caspase inhibitor Q-VD-Oph (R&D Systems, Minneapolis, MN) was
used at 50mM (HH) and 10 mM (MyLa). For inhibition of NF-kB
signaling, the I-kB kinase allosteric site inhibitor BMS-345541
(B9935; Sigma) was used at 3 mM with a pretreatment of 3 hours,
before NSAID treatment was started.
Apoptosis, cytotoxicity, and cell proliferation
Hypodiploid cells were quantified by flow cytometry (FACSCalibur
BD Biosciences, San Diego, CA) after propidium iodide staining
(Riccardi and Nicoletti, 2006). Cells were harvested by centrifuga-
tion and stained for 1 hour with propidium iodide (40 mgml1 in
0.1% sodium citrate, 0.1% Triton X-100). Data were evaluated by
CellQuest (BD Biosciences) or WinMDI software (Scripps Research
Institute, La Jolla, CA). Cytotoxicity was determined according to
lactate dehydrogenase release using a cytotoxicity detection kit
(Roche Diagnostics, Mannheim, Germany). Cell survival and
proliferation was quantified by the WST-1 assay (Roche Diagnostics)
according to mitochondrial enzyme activity. Cells were seeded in
96-well plates (15,000 cells per 100ml). After addition of WST-1
reagent, the absorbance at 450 nm was determined in an ELISA
reader. Data were reported in percentage of nontreated controls.
Direct cell counts were determined with a CASY Cell Counter (TTC
model, Scha¨rfe System, Reutlingen, Germany). Data were reported
in percentage of nontreated controls.
Western blot analysis
Detailed protocols for protein extraction and western blot analysis were
described previously (Eberle et al., 2003). Primary antibodies purchased
from Cell Signaling (Danvers, MA): caspase-8 (9746, 1:1,000); caspase-
9 (9502, 1:1,000); active caspase-3 (9661, 1:1,000); procaspase-3
(9662, 1:1,000); Bid (2002, 1:1,000); XIAP (2042, 1:1,000); Lamin A/C
(2032, 1:1,000). Antibodies obtained from Santa Cruz (Heidelberg,
Germany): c-FLIP (sc-5276, 1:200); Bax (sc-493, 1:200); Bcl-2 (sc-509,
1:200); Mcl-1 (sc-12756, 1:200); Survivin (sc-17779, 1:200); GAPDH
(sc-32233, 1:200); p65 (sc-109, 1:200); p50 (sc-1191, 1:200); p52
(sc-7386, 1:200). Antibodies such as cytochrome c (BD Biosciences,
1:1,000) and VDAC (Calbiochem, Nottingham, UK, 529536, 1:5,000)
were also used. As secondary antibodies, horseradish peroxidase-
labeled goat anti-rabbit and goat anti-mouse were used (Dako Cyto-
mation, Hamburg, Germany, 1:5,000). The quantification of c-FLIP
expression was obtained by densitometry.
TRAIL and TRAIL-R2/DR5 surface expression
Cells were harvested by centrifugation, washed with phosphate-
buffered saline (PBS), stained, and analyzed by flow cytometry.
Aliquots of 1 106 cells in 100 ml PBS with 1% BSA were incubated
for 30minutes in the dark with PE-conjugated TRAIL antibody
(RIK2, Santa Cruz, 1:5). PE-labeled isotype IgG1 antibody was
used (555749, BD Pharmingen, BD Bioscience, San Diego, CA) as
control. For determination of TRAIL-R2/DR5 surface expression,
cells were harvested as described above. After washing with PBS,
aliquots of 1 106 cells in 100 ml PBS, 1% BSA were incubated for
30minutes with mAb against TRAIL-R2/DR5 (Alexis, clone HS 201,
1:100). An isotypic monoclonal mouse IgG1 antibody (Alexis, clone
MOPC31C, 278-010, 1:100) was used as negative control. After
washing cells twice with PBS, they were incubated for 30minutes
with a secondary phycoerythrin-labeled goat anti-mouse IgG1
antiserum (Alexis, 211-201-C050; 1:100).
Mitochondrial activation, ROS, and NF-jB
For determination of cytochrome c release and Bax translocation to
mitochondria, cells were fractionated by a mitochondria/cytosol
fractionation kit (ALX-850-276, Alexis). For determination of the
mitochondrial membrane potential (Dcm) by flow cytometry,
harvested cells were stained with fluorescent tetramethylrhodamine
methyl ester perchlorate (TMRMþ , Sigma; 1mM, 15minutes, 37 1C).
For determination of intracellular ROS by flow cytometry, harvested
cells were stained with fluorescent 2,7-dichlorodihydrofluorescein
diacetate (Invitrogen, Eugene, OR, 50 mM, 15minutes, 37 1C).
Nuclear translocation of NF-kB subunits (p65, p50, and p52) was
determined by western blot analysis. The DNA-binding capacity of
NF-kB subunits was determined by an ELISA (TransAM NF-kB family
ELISA kit; Active Motif, Rixensart, Belgium). Cells (1.5 105 well)
were seeded in a culture flask and were treated with NSAIDs for
16 hours. Nuclear extracts were prepared with a nuclear extraction
kit (40010, Active Motif). Protein content was quantified using a
protein assay (BCA, Pierce, Bonn, Germany). Equal amounts of
nuclear proteins (6mg) were placed in 96-well plates coated with
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oligonucleotides covering the NF-kB consensus sequence. Binding
of NF-kB subunits to the immobilized oligonucleotides was detected
by subunit-specific antibodies, followed by immunostaining with
horseradish peroxidase-labeled secondary antibodies. The chromo-
genic reaction was measured at 450 nm in an ELISA reader.
Viral vectors
Previously described lentiviral vectors were used for c-FLIP shRNA
and control scramble shRNA expression (Rubinson et al., 2003;
Braun et al., 2010). Cell transduction had been described previously
(Al Yacoub et al., 2008). A retroviral vector was used for c-FLIPL
overexpression (Geserick et al., 2008), which was kindly provided
by Leverkus (Mannheim, Germany). Stably transduced MyLa cells
were isolated for zeocin resistance (ant-zn-1, InvivoGen, San Diego,
CA; 100–500 mgml1), because of a resistance gene encoded by the
retroviral vector. Transduction efficiencies were determined by flow
cytometric analysis for GFP.
Isolation and enrichment of tumor T cells from SzS patients
Peripheral blood mononuclear cells from venous blood collected
from SzS patients and healthy donors were isolated using density-
gradient centrifugation with Ficoll-Paque (GE Healthcare Bio-
Sciences, Uppsala, Sweden). Tumor T cells were identified by
sequencing of the dominant genomic TCR-b rearrangement and
were isolated using fluorochrome-conjugated Vb chain-specific
antibodies (Beckman Coulter), followed by incubation with anti-
fluorochrome microbeads (130-048-801, Miltenyi Biotec, Bergisch
Gladbach, Germany). Control T cells from healthy donors were
enriched according to CD4 expression (130-045-101, Miltenyi
Biotec). Purity of enriched cells was determined by flow cytometry
using antibodies for CD3, CD4, and CD8 (BD Biosciences). Blood
samples of four SzS patients were used (one male, three female;
mean age: 63 years). The study was conducted according to the
Declaration of Helsinki Principles. Patients had given written,
informed consent on the use of the blood samples for scientific
purposes. The collection and use of the probes was approved by the
Ethical Committee of the Charite´—Universita¨tsmedizin Berlin.
Statistics
Experiments usually consisted of triplicate values, and were
performed 2–3 times. Statistical significance was determined by
Student’s t-test and is indicated in the figures by asterisks (Po0.05).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This study was supported by the research fund of the Charite´–University
Medical Center Berlin. The c-FLIP retroviral vector was kindly provided by
Professor M Leverkus (Mannheim, Germany).
REFERENCES
Agrawal A, Fentiman IS (2008) NSAIDs and breast cancer: a possible
prevention and treatment strategy. Int J Clin Pract 62:444–9
Altieri DC (2010) Survivin and IAP proteins in cell-death mechanisms.
Biochem J 430:199–205
Al Yacoub N, Romanowska M, Krauss S et al. (2008) PPARdelta is a type 1
IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol
128:1940–9
Braun FK, Fecker LF, Schwarz C et al. (2007) Blockade of death receptor-
mediated pathways early in the signaling cascade coincides with distinct
apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest
Dermatol 127:2425–37
Braun FK, Hirsch B, Al Yacoub N et al. (2010) Resistance of cutaneous
anaplastic large-cell lymphoma cells to apoptosis by death ligands is
enhanced by CD30-mediated overexpression of c-FLIP. J Invest
Dermatol 130:826–40
Bresalier RS, Sandler RS, Quan H et al. (2005) Cardiovascular events
associated with rofecoxib in a colorectal adenoma chemoprevention
trial. N Engl J Med 352:1092–102
Castellone MD, Teramoto H, Williams BO et al. (2005) Prostaglandin E2
promotes colon cancer cell growth through a Gs-axin-beta-catenin
signaling axis. Science 310:1504–10
Cha YI, Dubois RN (2007) NSAIDs and cancer prevention: targets down-
stream of COX-2. Annu Rev Med 58:239–52
Chan K, Truong D, Shangari N et al. (2005) Drug-induced mitochondrial
toxicity. Expert Opin Drug Metab Toxicol 1:655–69
Clevers H (2006) Colon cancer—understanding how NSAIDs work. N Engl J
Med 354:761–3
Cole BF, Logan RF, Halabi S et al. (2009) Aspirin for the chemoprevention of
colorectal adenomas: meta-analysis of the randomized trials. J Natl
Cancer Inst 101:256–66
Contassot E, Gaide O, French LE (2007) Death receptors and apoptosis.
Dermatol Clin 25:487–501
Contassot E, Kerl K, Roques S et al. (2008) Resistance to FasL and tumor
necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in
Sezary syndrome T-cells associated with impaired death receptor and
FLICE-inhibitory protein expression. Blood 111:4780–7
Dikshit P, Chatterjee M, Goswami A et al. (2006) Aspirin induces apop-
tosis through the inhibition of proteasome function. J Biol Chem 281:
29228–35
Eberle J, Fecker LF, Forschner T et al. (2007) Apoptosis pathways as
promising targets for skin cancer therapy. Br J Dermatol 156
(Suppl 3):18–24
Eberle J, Fecker LF, Hossini AM et al. (2003) CD95/Fas signaling in human
melanoma cells: conditional expression of CD95L/FasL overcomes the
intrinsic apoptosis resistance of malignant melanoma and inhibits growth
and progression of human melanoma xenotransplants. Oncogene
22:9131–41
Fecker LF, Stockfleth E, Braun FK et al. (2010) Enhanced death ligand-induced
apoptosis in cutaneous SCC cells by treatment with diclofenac/
hyaluronic acid correlates with downregulation of c-FLIP. J Invest
Dermatol 130:2098–109
Fischer U, Janicke RU, Schulze-Osthoff K (2003) Many cuts to ruin: a
comprehensive update of caspase substrates. Cell Death Differ 10:76–100
Fredriksson L, Herpers B, Benedetti G et al. (2011) Diclofenac inhibits tumor
necrosis factor-alpha-induced nuclear factor-kappaB activation causing
synergistic hepatocyte apoptosis. Hepatology 53:2027–41
Geserick P, Drewniok C, Hupe M et al. (2008) Suppression of cFLIP is
sufficient to sensitize human melanoma cells to TRAIL and CD95L-
mediated apoptosis. Oncogene 27:3211–20
Gootenberg JE, Ruscetti FW, Mier JW et al. (1981) Human cutaneous T cell
lymphoma and leukemia cell lines produce and respond to T cell growth
factor. J Exp Med 154:1403–18
Greenhough A, Smartt HJ, Moore AE et al. (2009) The COX-2/PGE2 pathway:
key roles in the hallmarks of cancer and adaptation to the tumour
microenvironment. Carcinogenesis 30:377–86
Half E, Arber N (2009) Colon cancer: preventive agents and the present status
of chemoprevention. Expert Opin Pharmacother 10:211–9
Irmler M, Thome M, Hahne M et al. (1997) Inhibition of death receptor signals
by cellular FLIP. Nature 388:190–5
Jana NR (2008) NSAIDs and apoptosis. Cell Mol Life Sci 65:1295–301
Janssen EM, Droin NM, Lemmens EE et al. (2005) CD4+ T-cell help controls
CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.
Nature 434:88–93
438 Journal of Investigative Dermatology (2012), Volume 132
FK Braun et al.
NSAID-Induced Apoptosis in CTCL
Jendrossek V, Handrick R, Belka C (2003) Celecoxib activates a novel
mitochondrial apoptosis signaling pathway. FASEB J 17:1547–9
Kaltoft K, Bisballe S, Dyrberg T et al. (1992) Establishment of 2 continuous T-
cell strains from a single plaque of a patient with mycosis-fungoides.
In Vitro Cell Dev Biol 28:161–7
Kaltoft K, Bisballe S, Rasmussen HF et al. (1987) A continuous T-cell line from
a patient with Sezary syndrome. Arch Dermatol Res 279:293–8
Kiessling MK, Klemke CD, Kaminski MM et al. (2009) Inhibition of
constitutively activated nuclear factor-kappaB induces reactive oxygen
species- and iron-dependent cell death in cutaneous T-cell lymphoma.
Cancer Res 69:2365–74
Klemke CD, Brenner D, Weiss EM et al. (2009) Lack of T-cell receptor-
induced signaling is crucial for CD95 ligand up-regulation and protects
cutaneous T-cell lymphoma cells from activation-induced cell death.
Cancer Res 69:4175–83
Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and
aspirin. Science 265:956–9
Kopp KL, Kauczok CS, Lauenborg B et al. (2010) COX-2-dependent
PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia
24:1179–85
Krammer PH, Arnold R, Lavrik IN (2007) Life and death in peripheral T cells.
Nat Rev Immunol 7:532–42
Li HL, Zhu H, Xu CJ et al. (1998) Cleavage of BID by caspase 8
mediates the mitochondrial damage in the Fas pathway of apoptosis.
Cell 94:491–501
Li-Weber M, Krammer PH (2003) Function and regulation of the
CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol
15:145–57
Mathas S, Lietz A, Anagnostopoulos I et al. (2004) c-FLIP mediates resistance
of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis.
J Exp Med 199:1041–52
Micheau O, Lens S, Gaide O et al. (2001) NF-kappaB signals induce the
expression of c-FLIP. Mol Cell Biol 21:5299–305
Muller AM, Ihorst G, Mertelsmann R et al. (2005) Epidemiology of non-
Hodgkin’s lymphoma (NHL): trends, geographic distribution, and
etiology. Ann Hematol 84:1–12
Newsom-Davis T, Prieske S, Walczak H (2009) Is TRAIL the holy grail of
cancer therapy? Apoptosis 14:607–23
Nussmeier NA, Whelton AA, Brown MT et al. (2005) Complications of the
COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl
J Med 352:1081–91
Reed JC (2008) Bcl-2-family proteins and hematologic malignancies: history
and future prospects. Blood 111:3322–30
Reed JC, Pellecchia M (2005) Apoptosis-based therapies for hematologic
malignancies. Blood 106:408–18
Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide
staining and flow cytometry. Nat Protoc 1:1458–61
Rubinson DA, Dillon CP, Kwiatkowski AV et al. (2003) A lentivirus-based
system to functionally silence genes in primary mammalian cells, stem
cells and transgenic mice by RNA interference. Nat Genet 33:401–6
Rumore MM, Kim KS (2010) Potential role of salicylates in type 2 diabetes.
Ann Pharmacother 44:1207–21
Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E
synthase-1: a novel therapeutic target. Pharmacol Rev 59:207–24
Sors A, Jean-Louis F, Begue E et al. (2008) Inhibition of IkappaB kinase subunit
2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB
constitutive activation, induces cell death, and potentiates the apoptotic
response to antineoplastic chemotherapeutic agents. Clin Cancer Res
14:901–11
Sors A, Jean-Louis F, Pellet C et al. (2006) Down-regulating constitutive
activation of the NF-kappaB canonical pathway overcomes the resistance
of cutaneous T-cell lymphoma to apoptosis. Blood 107:2354–63
Starkebaum G, Loughran TP, Waters CA et al. (1991) Establishment of An Il-2
independent, human T-cell line possessing only the P70 Il-2 receptor. Int
J Cancer 49:246–53
Ulrich M, Drecoll U, Stockfleth E (2010) Emerging drugs for actinic keratosis.
Expert Opin Emerg Drugs 15:545–55
Willemze R, Jaffe ES, Burg G et al. (2005) WHO-EORTC classification for
cutaneous lymphomas. Blood 105:3768–85
Zhang CL, Kamarashev J, Qin JZ et al. (2003) Expression of apoptosis
regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol 200:
249–54
www.jidonline.org 439
FK Braun et al.
NSAID-Induced Apoptosis in CTCL
